Level C· Early human research exploring benefitsProspective StudyEurope PMC

Intra-operative preparation of autologous bone marrow-derived CD34-enriched cellular products for cardiac therapy

Donnenberg AD., Donnenberg VS., Griffin DL., Moore LR., Tekinturhan F., Kormos RL.

Prospective Study on Cardiovascular Disease, published in Cytotherapy (2011) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cytotherapy (2011)
Reported sample size
—
Source database
Europe PMC
PMID
21062114
PMCID
PMC4165076
DOI
10.3109/14653249.2010.529888
Citations
7

Abstract (original English)

Background and aims With the advent of regenerative therapy, there is renewed interest in the use of bone marrow as a source of adult stem and progenitor cells, including cell subsets prepared by immunomagnetic selection. Cell selection must be rapid, efficient and performed according to current good manufacturing practices. In this report we present a methodology for intra-operative preparation of CD34(+) selected autologous bone marrow for autologous use in patients receiving coronary artery bypass grafts or left ventricular assist devices. Methods and results We developed a rapid erythrocyte depletion method using hydroxyethyl starch and low-speed centrifugation to prepare large-scale (mean 359 mL) bone marrow aspirates for separation on a Baxter Isolex 300i immunomagnetic cell separation device. CD34 recovery after erythrocyte depletion was 68.3 ± 20.2%, with an average depletion of 91.2 ± 2.8% and an average CD34 content of 0.58 ± 0.27%. After separation, CD34 purity was 64.1 ± 17.2%, with 44.3 ± 26.1% recovery and an average dose of 5.0 ± 2.7 × 10(6) CD34(+) cells/product. In uncomplicated cases CD34-enriched cellular products could be accessioned, prepared, tested for release and administered within 6 h. Further analysis of CD34(+) bone marrow cells revealed a significant proportion of CD45(-) CD34(+) cells. Conclusions Intra-operative immunomagnetic separation of CD34-e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HeartHeart VentriclesBone Marrow CellsHumansAntigens, CD34Coronary Artery BypassIntraoperative PeriodTransplantation, AutologousFlow CytometryAged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research